Chenghao Yang1, Kim M Tiemessen2, Fokko J Bosker3, Klaas J Wardenaar4, Jie Lie5, Robert A Schoevers6. 1. Tianjin Mental Health Institute, Tianjin Anding Hospital, Tianjin, China; University Centre of Psychiatry, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands; University of Groningen, Research School Behavioral and Cognitive Neurosciences (BCN), Groningen, The Netherlands. 2. University Centre of Psychiatry, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands. 3. University Centre of Psychiatry, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands; University of Groningen, Research School Behavioral and Cognitive Neurosciences (BCN), Groningen, The Netherlands. Electronic address: f.j.bosker@umcg.nl. 4. University of Groningen, University Medical Center Groningen, Department of Psychiatry, Interdisciplinary Center Psychopathology and Emotion regulation (ICPE), Groningen, The Netherlands. 5. Tianjin Mental Health Institute, Tianjin Anding Hospital, Tianjin, China. 6. University Centre of Psychiatry, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands; University of Groningen, Research School Behavioral and Cognitive Neurosciences (BCN), Groningen, The Netherlands.
Abstract
OBJECTIVE: The current diagnostic criteria for major depressive disorder (MDD) do not allow prediction of prognosis and therapeutic response. A possible strategy to improve this situation is the identification of depression subtypes on the bases of biomarkers reflecting underlying pathological processes such as neuro-inflammation. METHODS: The PubMed/Medline database was searched until Apr 25th, 2017. In the initial search 1018 articles were retrieved, which were subsequently screened and only selected when the inclusion and exclusion criteria were fulfilled. RESULTS: Eight eligible studies were found. Overall, serum interleukin-6 and 1β values were increased in the melancholic MDD subtype compared to controls and the non-melancholic MDD subtype. C-reactive protein was increased in non-melancholic MDD in 2 out of 4 studies, while there was no difference for tumor necrosis factor-α and interleukin-2 and 10. CONCLUSION: Given the paucity of eligible studies the tentative conclusion must be drawn that peripheral inflammation markers have limited added value thus far to distinguish between melancholic and non-melancholic depression. To allow for a more definitive conclusion, further research is warranted using a broader panel of inflammatory markers in MDD subtypes, preferably based on a general consensus regarding diagnostic criteria and subtype definitions.
OBJECTIVE: The current diagnostic criteria for major depressive disorder (MDD) do not allow prediction of prognosis and therapeutic response. A possible strategy to improve this situation is the identification of depression subtypes on the bases of biomarkers reflecting underlying pathological processes such as neuro-inflammation. METHODS: The PubMed/Medline database was searched until Apr 25th, 2017. In the initial search 1018 articles were retrieved, which were subsequently screened and only selected when the inclusion and exclusion criteria were fulfilled. RESULTS: Eight eligible studies were found. Overall, serum interleukin-6 and 1β values were increased in the melancholic MDD subtype compared to controls and the non-melancholic MDD subtype. C-reactive protein was increased in non-melancholic MDD in 2 out of 4 studies, while there was no difference for tumor necrosis factor-α and interleukin-2 and 10. CONCLUSION: Given the paucity of eligible studies the tentative conclusion must be drawn that peripheral inflammation markers have limited added value thus far to distinguish between melancholic and non-melancholic depression. To allow for a more definitive conclusion, further research is warranted using a broader panel of inflammatory markers in MDD subtypes, preferably based on a general consensus regarding diagnostic criteria and subtype definitions.
Authors: Sarah A Keaton; Zachary B Madaj; Patrick Heilman; LeAnn Smart; Jamie Grit; Robert Gibbons; Teodor T Postolache; Kimberly Roaten; Eric D Achtyes; Lena Brundin Journal: J Affect Disord Date: 2019-01-03 Impact factor: 4.839
Authors: Malcolm P Forbes; Adrienne O'Neil; Melissa Lane; Bruno Agustini; Nick Myles; Michael Berk Journal: Drugs Aging Date: 2021-04-29 Impact factor: 3.923
Authors: N Heym; B C Heasman; K Hunter; S R Blanco; G Y Wang; R Siegert; A Cleare; G R Gibson; V Kumari; A L Sumich Journal: Psychopharmacology (Berl) Date: 2019-04-07 Impact factor: 4.530